CN107007623A - It is a kind of to treat compound liquor merbromin of otitis and preparation method thereof - Google Patents
It is a kind of to treat compound liquor merbromin of otitis and preparation method thereof Download PDFInfo
- Publication number
- CN107007623A CN107007623A CN201710397167.XA CN201710397167A CN107007623A CN 107007623 A CN107007623 A CN 107007623A CN 201710397167 A CN201710397167 A CN 201710397167A CN 107007623 A CN107007623 A CN 107007623A
- Authority
- CN
- China
- Prior art keywords
- parts
- otitis
- merbromin
- liquor merbromin
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SQFDQLBYJKFDDO-UHFFFAOYSA-K merbromin Chemical compound [Na+].[Na+].C=12C=C(Br)C(=O)C=C2OC=2C([Hg]O)=C([O-])C(Br)=CC=2C=1C1=CC=CC=C1C([O-])=O SQFDQLBYJKFDDO-UHFFFAOYSA-K 0.000 title claims abstract description 75
- 229960002782 merbromin Drugs 0.000 title claims abstract description 70
- 208000005141 Otitis Diseases 0.000 title claims abstract description 44
- 150000001875 compounds Chemical class 0.000 title claims abstract description 43
- 208000019258 ear infection Diseases 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title abstract description 8
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 claims abstract description 32
- 229960001907 nitrofurazone Drugs 0.000 claims abstract description 32
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims abstract description 26
- RXXROIWDLGTUIN-UHFFFAOYSA-N zinc;(4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide Chemical compound [Zn+2].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1.C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 RXXROIWDLGTUIN-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 17
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 13
- 229960004125 ketoconazole Drugs 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 13
- KTCCKNDTESWMHC-UHFFFAOYSA-N [Br].[Hg] Chemical compound [Br].[Hg] KTCCKNDTESWMHC-UHFFFAOYSA-N 0.000 claims description 5
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 2
- 229910052753 mercury Inorganic materials 0.000 claims description 2
- IGWHDMPTQKSDTL-JXOAFFINSA-N TMP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IGWHDMPTQKSDTL-JXOAFFINSA-N 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 241000894006 Bacteria Species 0.000 abstract description 19
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 230000001954 sterilising effect Effects 0.000 abstract description 5
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 abstract description 4
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 24
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 16
- 229960001082 trimethoprim Drugs 0.000 description 15
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 14
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 14
- 229940124530 sulfonamide Drugs 0.000 description 14
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 235000019260 propionic acid Nutrition 0.000 description 6
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- 206010033078 Otitis media Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229940008716 mercurochrome Drugs 0.000 description 5
- 206010033072 otitis externa Diseases 0.000 description 5
- LBDIKIOMFGWKNT-UHFFFAOYSA-N pyrimidine;zinc Chemical compound [Zn].C1=CN=CN=C1 LBDIKIOMFGWKNT-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- 239000005864 Sulphur Substances 0.000 description 4
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 4
- 229940092705 beclomethasone Drugs 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 241000726221 Gemma Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PCFUWBOSXMKGIP-UHFFFAOYSA-N 2-benzylpyridine Chemical compound C=1C=CC=NC=1CC1=CC=CC=C1 PCFUWBOSXMKGIP-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 229940117937 Dihydrofolate reductase inhibitor Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000122862 Fonsecaea Species 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241000228150 Penicillium chrysogenum Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- 108010014404 dihydrofolate synthetase Proteins 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- BQPIGGFYSBELGY-UHFFFAOYSA-N mercury(2+) Chemical compound [Hg+2] BQPIGGFYSBELGY-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 208000004594 persistent fetal circulation syndrome Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- -1 sulphur Amine Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 208000025301 tympanitis Diseases 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/345—Nitrofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of compound liquor merbromin for treating otitis and preparation method thereof, the compound liquor merbromin includes the raw material of following parts by weight：10 20 parts of liquor merbromin, 0.1 0.5 parts of furacilin solution, 0.01 0.5 parts of sulfadiazine zinc, 0.001 0.01 parts of beclomeasone propionate.Its preparation method is that sulfadiazine zinc, beclomeasone propionate and furacilin solution are respectively implanted into liquor merbromin to mix, until being completely dissolved, is produced.Liquor merbromin, furacilin solution, sulfadiazine zinc and beclomeasone propionate are carried out scientific compatibility by the present invention, and small toxicity is safe, the therapeutic effect of anti-inflammatory sterilization can either be reached, inhibitory action can be played to the drug-fast bacteria of bacterial infection skin again, curative effect is reliable, does not recur.
Description
Technical field
The present invention relates to a kind of medicine for treating otitis, specially it is a kind of liquor merbromin is compounded obtained by control
Treat medicine of otitis and preparation method thereof.
Background technology
Mercurochrome, organic compound, the i.e. bromo- 4- hydroxyls mercuri fluorescein double sodium salts of 2,7- bis-；Also known as merbromin, with green or
Bluish-green foxy small pieces or particle, it is soluble in water, ethanol and acetone are slightly soluble in, insoluble in chloroform and ether, its aqueous solution is in
Cherry red or kermesinus, it is adaptable to the sterilization of the shallow surface of a wound skin injury of table.
The aqueous solution of mercurochrome 2%, is commonly called as mercurochrome, is one of ancient medicine, has for small area wound notable
Curative effect, combined after its mercury ion dissociation with protein, so as to play bactericidal action, but its bactericidal action is weaker, to gemma
Invalid, current therapeutic domain is small, is generally only used for wound, the disinfective action of small area skin and mucosa；In addition because mercury is
A kind of hypertoxic non-essential element, is the higher external sterilizing preservative of security if proper use of, will if using accidentally
It can produce larger toxic side effect, therefore this invisible is caused to crowds such as infant patient guardian or Patients with Big Area Burn
The feared state of mind, and then limit researcher to liquor merbromin newly developed and utilize.
Otitis is the more intractable disease of clinician for many years, common otitis include otitis media suppurative, otitis externa,
External auditory meatus fungal infection etc., is national common disease, and refractory treatment is also compared relatively, summer is mainly in, after especially swimming or abrading,
Due to hot and humid bacterium or mould can be promoted to mushroom out, and incubation period lasts can be first in after mould implantation keratoderma
A couple of days or several weeks, then invade epithelium top layer and cause inflammation up to proliferation period, it is asymptomatic in the implantation phase of mould or incubation period,
Only in proliferation period mould just can amount reproduction, and with a large amount of epithalaxias, ear itching, swell and ache, pyorrhea, tinnitus, under hearing
The symptoms such as drop, therefore otitis is difficult to treat, does not there is reliable treatment method always at present.
Liquor merbromin is used to treat the otitis such as otitis externa, otitis media suppurative with symptom management in related magazine text
Offer on the books, but curative effect is not good enough, such as Chinese Journal of Otorhinolaryngology-skull Base Surgery in March, 1997 the 1st phase of volume 3, compound mercurochrome
Preparation for treating mycotic otitis externa, its prescription is chloramphenicol, dexamethasone, ethanol, glycerine etc., and the prescription is treated initial stage to otitis
Effect is preferable, but prescription is complicated, it is easy to recur, curative effect is not good enough.
The content of the invention
In order to solve the above mentioned problem of prior art presence, the invention provides a kind of compound mercurochrome for treating otitis is molten
Liquid and preparation method thereof, the compound liquor merbromin small toxicity for the treatment of otitis provided by the present invention, the treatment that can either be reached
Effect, can play inhibitory action to the drug-fast bacteria of bacterial infection skin again, and compound liquor merbromin prescription of the invention is simple, treats
Effect is all good, and its preparation method is simple, and easy to use, curative effect is reliable.
A kind of compound liquor merbromin for treating otitis, includes the raw material of following parts by weight：
10-20 parts of liquor merbromin, 0.1-0.5 parts of furacilin solution, 0.01-0.5 parts of sulfadiazine zinc, propionic acid times chlorine
0.001-0.01 parts of pine of rice.
The present invention is using liquor merbromin as solvent, addition furacilin solution, sulfadiazine zinc and beclomeasone propionate
Synergistic antimicrobial is carried out, the inflammation such as otitis media suppurative, otitis externa, external auditory meatus pruritus can be treated, by the compound of the present invention
Liquor merbromin is dripped at ear inflammation, focus capable of washing, eliminate foreign matter, compound liquor merbromin of the invention have anti-inflammatory,
Convergence, the rotten effect that disappears of detoxifying.Nitrofurazone therein can disturb the glycometabolism process and oxidase system of bacterium and play suppression
Bacterium or bactericidal action, the early stage of main interference bacterium glycometabolism cause bacterial metabolism disorderly and dead.Its antimicrobial spectrum compared with
Extensively, there is antibacterial action to a variety of Grain-positives and negative bacterium, also have effect to anaerobic bacteria, to Pseudomonas and Proteus
There is drug resistance, have suitable effect to the bacterium infection caused by mould, in the case that nitrofurazone is even at having fester
It can be absorbed by the skin to play the curative effect of anti-inflammatory；
Sulfadiazine zinc is topical application sulfa drug, the effect with both sulphadiazine and zinc, to most Grain-positives
Bacterium, gram-negative bacteria, saccharomycete and other fungies have good antibacterial action, and not by p-aminobenzoic acid institute antagonism, wherein
Zinc is because that can destroy the DNA structure of bacterium, also with bacteriostasis, therefore sulfadiazine zinc can compensate for the zinc loss of patient, and increases
Strong body resistance infection and wound healing ability；
The potent external application glucocorticoids medicine of beclomeasone propionate system, it is local with anti-inflammatory, antiallergy and the effect such as antipruritic
Antiinflammatory action is 5 times of the similar drugs such as fluocinolone acetonide and triamcinolone, and its lipophilicity is stronger, easily infiltration, after being applied to affected part 30 minutes
It can come into force, beclomeasone propionate also has no significant effect to body temperature and urination, and therefore, local topical will not suppress Human Cortex's work(
Energy and the adverse reaction caused by cortex hormone function is disorderly.
The present invention presses above-mentioned parts by weight by liquor merbromin, furacilin solution, sulfadiazine zinc and beclomeasone propionate
Scientific compatibility is carried out, small toxicity is safe, the therapeutic effect of anti-inflammatory sterilization can either be reached, again can be to bacterial infection skin
Drug-fast bacteria play inhibitory action, curative effect is reliable, does not recur.
Preferably：A kind of compound liquor merbromin for treating otitis, includes the raw material of following parts by weight：Liquor merbromin
15-20 parts, 0.1-0.3 parts of furacilin solution, 0.01-0.1 parts of sulfadiazine zinc, 0.001-0.005 parts of beclomeasone propionate.
Preferably：A kind of compound liquor merbromin for treating otitis, includes the raw material of following parts by weight：Liquor merbromin 20
Part, 0.1 part of furacilin solution, 0.01 part of sulfadiazine zinc, 0.001 part of beclomeasone propionate.
Preferably：The mass percentage concentration of the liquor merbromin is 2%；The quality percentage of the furacilin solution is dense
Spend for 2%.
Preferably：The compound liquor merbromin of the treatment otitis also includes the TMP of 0.001-0.01 parts by weight.
In order to further increase the curative effect of the present invention, its antibiotic property is improved, TMP, wherein methoxy are added in formula
The mechanism of action of benzyl pyridine is：TMP is bacterium dihydrofolate reductase inhibitor, belongs to sulfanilamide (SN) medicine synergist, its antimicrobial spectrum and sulphur
Amine medicine is similar, plays the role of to suppress dihyrofolate reductase, but bacterium is relatively also easy to produce drug resistance, is seldom used alone, and sulfanilamide (SN)
Medicine then suppresses dihydrofolate synthetase, and both are shared, and can make the folic acid metabolism of bacterium by double blocking, thus antibacterial action
Increase substantially (can synergy several times to tens times), therefore have the title of trimethoprim (TMP), and the appearance of drug resistance strain can be reduced.
Dynamics shows that TMP oral absorption completely, up to more than the 90% of dosage, is widely distributed after absorption
In the tissue and body fluid of whole body, blood-brain barrier is may pass through, cerebrospinal fluid drug concentration is up to haemoconcentration in meninx inflammation
50-100%, may pass through placenta and enters in fetus body, fetal circulation blood concentration is close with parent blood concentration, and the product are mainly through kidney
Discharge rate is the 40-60% of dosage in excretion, 24h urine：Wherein 80-90% is discharged with medicine original shape, and product t1/2 is 8-
10h。
Further：The compound liquor merbromin of the treatment otitis media suppurative also includes the ketone of 0.1-0.5 parts by weight
Health azoles.
Due to part in diffuse flush swelling ear channel skin can with a small amount of secretion, these secretion can cultivate with
The fungies such as candida albicans, Fluorene shapes bacterium, Penicillium notatum staphylococcus aureus, Pseudomonas aeruginosa, further draw repeatedly with the breeding of fungi
Inflammation is played, for such a fungal infection symptom, preferably, adding ketoconazole in formula, it is antimycotic that ketoconazole belongs to pyroles
Medicine, to deep infection fungi such as Mycotoruloides, Fonsecaea, Coccidioides, tissue milk born of the same parents Pseudomonas, Sporothrix etc.
Have antibacterial action, also have antibacterial activity to trichophyta etc., it is the work by interference cell pigment P -450 that ketone health, which frustrates pharmacological action,
Property, so as to suppress the biosynthesis of fungal cell membrane major sterols class-ergosterol, damage fungal cell membrane and to change its penetrating
Property, so that important intracellular matter leakage, ketone health frustrates the biosynthesis of the triacylglycerol and phosphatide that can suppress fungi, suppress oxygen
Change the activity of enzyme and peroxidase, cause intracellular hydrogen peroxide accumulation to cause cell submicroscopic structure to be denatured and meronecrosis, it is right
Candida albicans can then suppress its process for being changed into aggressive mycelia from gemma.
Addition ketone health, which is frustrated, in the present invention can effectively treat the symptoms such as external auditory meatus fungal infection.
Further：The sulfadiazine zinc, beclomeasone propionate, the particle diameter of TMP and ketoconazole are respectively less than
0.2mm。
A kind of method for the compound liquor merbromin for preparing the treatment otitis, step includes：By the sulphur of above-mentioned parts by weight
Amic metadiazine zinc, beclomeasone propionate and furacilin solution are respectively implanted liquor merbromin mixing, until be completely dissolved,
Produce.
A kind of method for the compound liquor merbromin for preparing the treatment otitis, step includes：By the sulphur of above-mentioned parts by weight
Amic metadiazine zinc, beclomeasone propionate, TMP and furacilin solution are respectively implanted liquor merbromin mixing, until
It is completely dissolved, produces.
A kind of method for the compound liquor merbromin for preparing the treatment otitis, step includes：By the sulphur of above-mentioned parts by weight
Amic metadiazine zinc, beclomeasone propionate, TMP, ketoconazole and furacilin solution are respectively implanted liquor merbromin mixing and stirred
Mix, until being completely dissolved, produce.
Beneficial effects of the present invention are：
Liquor merbromin, furacilin solution, sulfadiazine zinc and beclomeasone propionate are carried out scientific compatibility by the present invention,
Small toxicity, it is safe, the therapeutic effect of anti-inflammatory sterilization can either be reached, suppression can be played to the drug-fast bacteria of bacterial infection skin again
Make and use, curative effect is reliable, does not recur.
Embodiment
To make the object, technical solutions and advantages of the present invention clearer, technical scheme will be carried out below
Detailed description.Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Base
Embodiment in the present invention, those of ordinary skill in the art are resulting on the premise of creative work is not made to be owned
Other embodiment, belongs to the scope that the present invention is protected.
In example below 1g is represented with 1 part.
Embodiment 1
A kind of compound liquor merbromin for treating otitis, includes the raw material of following parts by weight：
2wt% 10 parts of liquor merbromin, 2wt% 0.01 part of 0.1 part of furacilin solution, sulfadiazine zinc, propionic acid
0.001 part of beclomethasone.
A kind of method for the compound liquor merbromin for preparing the treatment otitis, step is included the sulfanilamide (SN) of above-mentioned parts by weight
Pyrimidine zinc, beclomeasone propionate are crushed to the particle that particle diameter is 0.2mm respectively, are then mixed, and obtain first material, will be described
The liquor merbromin that first material and the 2wt% of above-mentioned parts by weight furacilin solution are respectively implanted 2wt% is mixed, directly
To being completely dissolved, produce.
Embodiment 2
A kind of compound liquor merbromin for treating otitis, includes the raw material of following parts by weight：
2wt% 17 parts of liquor merbromin, 2wt% 0.3 part of 0.15 part of furacilin solution, sulfadiazine zinc, propionic acid
0.002 part of beclomethasone, 0.003 part of TMP.
A kind of method for the compound liquor merbromin for preparing the treatment otitis, step is included the sulfanilamide (SN) of above-mentioned parts by weight
Pyrimidine zinc, beclomeasone propionate, TMP are crushed to the particle that particle diameter is 0.18mm respectively, are then mixed, obtain first
Material, the furacilin solution of the first material and the 2wt% of above-mentioned parts by weight is respectively implanted 2wt% liquor merbromin
Mix, until being completely dissolved, produce.
Embodiment 3
A kind of compound liquor merbromin for treating otitis, includes the raw material of following parts by weight：
2wt% 20 parts of liquor merbromin, 2wt% 0.01 part of 0.1 part of furacilin solution, sulfadiazine zinc, propionic acid
0.001 part of beclomethasone, 0.001 part of TMP, 0.1 part of ketoconazole.
A kind of method for the compound liquor merbromin for preparing the treatment otitis, step is included the sulfanilamide (SN) of above-mentioned parts by weight
Pyrimidine zinc, beclomeasone propionate, TMP, ketoconazole are crushed to the particle that particle diameter is 0.15mm respectively, are then mixed,
First material is obtained, the furacilin solution of the first material and the 2wt% of above-mentioned parts by weight is respectively implanted to 2wt% mercury bromine
Red solution is mixed, until being completely dissolved, is produced.
Embodiment 4
A kind of compound liquor merbromin for treating otitis, includes the raw material of following parts by weight：
2wt% 18 parts of liquor merbromin, 2wt% 0.4 part of 0.2 part of furacilin solution, sulfadiazine zinc, propionic acid times
0.003 part of chlorine rice pine, 0.006 part of TMP, 0.3 part of ketoconazole.
A kind of method for the compound liquor merbromin for preparing the treatment otitis, step is included the sulfanilamide (SN) of above-mentioned parts by weight
Pyrimidine zinc, beclomeasone propionate, TMP, ketoconazole are crushed to the particle that particle diameter is 0.14mm respectively, are then mixed,
First material is obtained, the furacilin solution of the first material and the 2wt% of above-mentioned parts by weight is respectively implanted to 2wt% mercury bromine
Red solution is mixed, until being completely dissolved, is produced.
Embodiment 5
A kind of compound liquor merbromin for treating otitis, includes the raw material of following parts by weight：
2wt% 18 parts of liquor merbromin, 2wt% 0.045 part of 0.4 part of furacilin solution, sulfadiazine zinc, propionic acid
0.008 part of beclomethasone, 0.008 part of TMP, 0.4 part of ketoconazole.
A kind of method for the compound liquor merbromin for preparing the treatment otitis, step is included the sulfanilamide (SN) of above-mentioned parts by weight
Pyrimidine zinc, beclomeasone propionate, TMP, ketoconazole are crushed to the particle that particle diameter is 0.14mm respectively, are then mixed,
First material is obtained, the furacilin solution of the first material and the 2wt% of above-mentioned parts by weight is respectively implanted to 2wt% mercury bromine
Mix, until being completely dissolved, produce in red solution.
The application method of compound liquor merbromin of present invention treatment otitis is：
1st, first using hydrogen peroxide cleaning purulent secretion (medical hydrogen peroxide can kill pathogenic entero becteria, pyococcus,
Surface disinfection is generally used for, this oxygen atom for being not yet combined into oxygen molecule, with very strong oxidability, connects with bacterium
When touching, microorganism can be destroyed, bacterium is killed).
2nd, compound liquor merbromin is dripped into 3-5 drops in ear inflammation affected part, the next day once, until subjective symptoms disappearance 3-5
Day (excitant is weaker than hydrogen peroxide).
Patient's treatment：
Case 1
Mr. Wang, man 40 years old, airport property before 5 years after pedicure, is very itched, many places, which are sought medical advice, not to improve after doing ear candle health care.
Ears are itched and gone to a doctor.Diagnoses and treatment is carried out to here, it is found that patient's bilateral external auditory meatus has white filiform and dry scab, is diagnosed as
Otitis externa merges fungal infection, when being treated by above-mentioned treatment method, find first day bilateral drip after hydrogen peroxide foam compared with
It is many, treatment 8 times is then carried out, cures, does not recur.
Case 2
Granddaughter scholar, firmly, there is otitis media suppurative medical history in airport south building, in more than 10 years of dysaudia, is listened in the spring in 2015
Power declines the phenomenon aggravated with tinnitus, is then gone to a doctor to here, and its symptom is covered with grey for left side external auditory meatus and earwaxed, dioxygen
Formed after water immersion and become milky, earwaxed and be changed into elasticity, be then diagnosed as Cholesteatomatous Tympanitis, at the initial stage for the treatment of, through three times
Hydrogen peroxide cleaning after, further soaked with sodium bicarbonate injection and clear up purulent secretion, the roomy deformity of duct of regarding sb. as an outsider, after adopt
With more than 10 healings of ear of compound liquor merbromin drop, do not recur always now.
Case 3
Mrs Xiao, 36 years old, address Beijing west city, double were suppurated for more than 20 years, were performed the operation after once expectant treatment is invalid, 2000 years
In certain hospital's row mastoidotympanectomy, auditory rehabilitation art recurs after 1 year.It is in July, 2015, medical to here.Symptom is outside bilateral
Duct purulent secretion, external auditory meatus is roomy, and the state of mind is not good enough, and trick is cool, and constitution is trembled with fear, and is diagnosed as postoperative recurrence patient, treats
Process is：Bilateral external auditory meatus purulent secretion first is rinsed with hydrogen peroxide, then ear is dripped 2 months with compound liquor merbromin, first
In all once a day, the next day second week starts or 2 days once, twice, healing after 2 months, auxiliary examination is as good as 2 weeks one week afters
Often, without other chronic diseases, do not recur so far.
The foregoing is only a specific embodiment of the invention, but protection scope of the present invention is not limited thereto, any
Those familiar with the art the invention discloses technical scope in, change or replacement can be readily occurred in, should all be contained
Cover within protection scope of the present invention.Therefore, protection scope of the present invention should be based on the protection scope of the described claims.
Claims (10)
1. a kind of compound liquor merbromin for treating otitis, it is characterised in that include the raw material of following parts by weight：
10-20 parts of liquor merbromin, 0.1-0.5 parts of furacilin solution, 0.01-0.5 parts of sulfadiazine zinc, beclomeasone propionate
0.001-0.01 parts.
2. the compound liquor merbromin for the treatment of otitis according to claim 1, it is characterised in that including following parts by weight
Raw material：
15-20 parts of liquor merbromin, 0.1-0.3 parts of furacilin solution, 0.01-0.1 parts of sulfadiazine zinc, beclomeasone propionate
0.001-0.005 parts.
3. the compound liquor merbromin for the treatment of otitis according to claim 2, it is characterised in that including following parts by weight
Raw material：
20 parts of liquor merbromin, 0.1 part of furacilin solution, 0.01 part of sulfadiazine zinc, 0.001 part of beclomeasone propionate.
4. the compound liquor merbromin of otitis is treated according to any one of claim 1-3, it is characterised in that the mercury bromine
The mass percentage concentration of red solution is 2%；The mass percentage concentration of the furacilin solution is 2%.
5. the compound liquor merbromin of otitis is treated according to any one of claim 1-3, it is characterised in that the treatment
The compound liquor merbromin of otitis also includes the TMP of 0.001-0.01 parts by weight.
6. the compound liquor merbromin for the treatment of otitis according to claim 5, it is characterised in that the treatment otitis is answered
Square liquor merbromin also includes the ketoconazole of 0.1-0.5 parts by weight.
7. the compound liquor merbromin for the treatment of otitis according to claim 6, it is characterised in that the sulfadiazine zinc,
The particle diameter of beclomeasone propionate, TMP and ketoconazole is respectively less than 0.2mm.
8. a kind of method for preparing the compound liquor merbromin that otitis is treated as any one of claim 1-3, its feature
It is, step includes：The sulfadiazine zinc, beclomeasone propionate and furacilin solution of above-mentioned parts by weight are respectively implanted mercury
The red solution of bromine is mixed, until being completely dissolved, is produced.
9. a kind of method for preparing the compound liquor merbromin for the treatment of otitis as claimed in claim 5, it is characterised in that step bag
Include：The sulfadiazine zinc of above-mentioned parts by weight, beclomeasone propionate, TMP and furacilin solution are respectively implanted mercury bromine
Red solution is mixed, until being completely dissolved, is produced.
10. a kind of method for preparing the compound liquor merbromin for the treatment of otitis as claimed in claims 6 or 7, it is characterised in that step
Suddenly include：By the sulfadiazine zinc of above-mentioned parts by weight, beclomeasone propionate, TMP, ketoconazole and furacilin solution
Liquor merbromin mixing is respectively implanted, until being completely dissolved, is produced.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710397167.XA CN107007623A (en) | 2017-05-31 | 2017-05-31 | It is a kind of to treat compound liquor merbromin of otitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710397167.XA CN107007623A (en) | 2017-05-31 | 2017-05-31 | It is a kind of to treat compound liquor merbromin of otitis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107007623A true CN107007623A (en) | 2017-08-04 |
Family
ID=59451040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710397167.XA Pending CN107007623A (en) | 2017-05-31 | 2017-05-31 | It is a kind of to treat compound liquor merbromin of otitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107007623A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101090707A (en) * | 2004-12-09 | 2007-12-19 | 拜耳医药保健股份公司 | Medicament for hygienic application inside the ear |
-
2017
- 2017-05-31 CN CN201710397167.XA patent/CN107007623A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101090707A (en) * | 2004-12-09 | 2007-12-19 | 拜耳医药保健股份公司 | Medicament for hygienic application inside the ear |
Non-Patent Citations (1)
| Title |
|---|
| 伍干元等: "复方汞溴红制剂治疗霉菌性外耳道炎", 《中国耳鼻咽喉颅底外科杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1740166B1 (en) | Therapeutic antimicrobial compositions and methods | |
| US8632823B2 (en) | Treatment of infected tissues with hypochlorous acid | |
| EP2525803B1 (en) | Antimicrobial agentcomprising peroxide, alcohol and chelating agent | |
| CN106421217B (en) | A kind of solution of benzalkonium chloride and preparation method thereof | |
| CN108420789B (en) | Benzalkonium chloride solution for external use and preparation method thereof | |
| US4708873A (en) | Method of chemically debriding uncerated necrotic tissue | |
| CN104619330B (en) | The preparation comprising hypochlorite and amino acid for treat wound and sore | |
| CA2710506C (en) | Use of aqueous solutions of ascorbic acid in the treatment of disorders of the eustachian tube | |
| CN107519236A (en) | A kind of topical agent for treating onychomycosis | |
| CN101584689B (en) | Compound eardrops containing antipyrine and lidocaine the and preparation method thereof | |
| BR112017027349B1 (en) | METHOD TO IMPROVE HEALTH BENEFITS | |
| CN102526056B (en) | Voriconazole ear drop and preparation method and application thereof | |
| CN108042626A (en) | It is a kind of have to remove earwax and the composition of bacteriostasis efficacy, preparation and its application | |
| CN108926577A (en) | A kind of method that electric potential water is used for Wound antibiotic healing cleaning-nursing | |
| CN107007623A (en) | It is a kind of to treat compound liquor merbromin of otitis and preparation method thereof | |
| West | A palliative approach to the management of malodour from malignant fungating tumours | |
| JPH10236961A (en) | Ophthalmic agent using electrolytic acid water | |
| CN112972516B (en) | A disinfectant product for treating otitis externa | |
| CN116115683B (en) | Honeysuckle antibacterial liquid and preparation method thereof | |
| CN117244009A (en) | Novel auditory canal antibacterial gel | |
| CN107737131A (en) | A kind of skin and mucosa damages antibacterial disinfectant and preparation method | |
| MX2007006334A (en) | Pharmaceutical composition comprising the combinaton of an anti-microbial agent and an antioxidant agent for the treatment of urinary infections. | |
| CN106562964A (en) | External-use ointment for treating beriberi | |
| Panchal et al. | Fungal otitis externa and tympanic membrane perforation. | |
| WO2023018767A1 (en) | Antimicrobial bladder additives system and method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170804 |